Regentis Biomaterials (RGNT) has obtained approval from the European Notified Body to manufacture its knee cartilage repair product GelrinC using its next-generation solvent-free manufacturing process, the company said Wednesday.
The manufacturing process increases production yield fivefold and improves efficiency and scalability, the company said.
Regentis prepares to commercially launch the product in Europe, it said.
Price: 2.59, Change: +0.09, Percent Change: +3.56
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.